Search Results - "amyloid"

Adapting proteostasis to ameliorate aggregation-associated amyloid diseases

Table of Contents: “…Contents: Protein folding, misfolding, aggregation -- The proteostasis network and its regulation -- Gain and loss of function diseases -- The transthyretin (TTR) amyloidosis -- Kinetic stabilizers & clinical trial results -- Tafamidis & Diflunisal: evidence for the amyloid hypothesis -- Improving protein misfolding/aggregation diseases -- The unfolded protein response (UPR) and its arm-selective activators -- ATF6 activation & reduction of TTR mutant -- Clinical trials in amyloidosis with cardiac involvement.…”
Get full text
Series

Adapting proteostasis to ameliorate aggregation-associated amyloid diseases

Table of Contents: “…Contents: Protein folding, misfolding, aggregation -- The proteostasis network and its regulation -- Gain and loss of function diseases -- The transthyretin (TTR) amyloidosis -- Kinetic stabilizers & clinical trial results -- Tafamidis & Diflunisal: evidence for the amyloid hypothesis -- Improving protein misfolding/aggregation diseases -- The unfolded protein response (UPR) and its arm-selective activators -- ATF6 activation & reduction of TTR mutant -- Clinical trials in amyloidosis with cardiac involvement.…”
Get full text
Series

Adapting proteostasis to ameliorate aggregation-associated amyloid diseases

Table of Contents: “…Contents: Protein folding, misfolding, aggregation -- The proteostasis network and its regulation -- Gain and loss of function diseases -- The transthyretin (TTR) amyloidosis -- Kinetic stabilizers & clinical trial results -- Tafamidis & Diflunisal: evidence for the amyloid hypothesis -- Improving protein misfolding/aggregation diseases -- The unfolded protein response (UPR) and its arm-selective activators -- ATF6 activation & reduction of TTR mutant -- Clinical trials in amyloidosis with cardiac involvement.…”
Get full text
Series

Abeta toxicity Part 2 /

Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity Part 1 /

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity 2

Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity 2

Table of Contents: “…Contents: The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing -- Methodology: key outcomes -- Abeta and amyloid imaging -- The progression of AD -- Abeta and memory -- Prediction of conversion from HC to MCI/AD -- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials -- Longitudinal PiB PET follow-up -- Plasma Abeta 42 levels in the PiB-PET AIBL subset -- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR -- Plasma ApoE (total) levels: the AIBL study -- Biomarker discovery -- Abeta deposition.…”
Get full text
Series (Alzheimer's disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity 1

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Abeta toxicity 1

Table of Contents: “…Contents: The amyloid plaque -- Impact of delaying onset of AD -- The amyloidocentric theory of Alzheimer's disease -- Compelling evidence for the Abeta theory of AD -- Delay onset of AD by 5 years -- The best target for a disease-modifying drug -- APP structure and domains -- Iron-export ferroxidase activity of beta-amyloid precursor protein -- Age at onset correlates with Abeta isoforms -- Activation of PS1 -- Abeta amyloid -- The mechanism of neurodegeneration -- Abeta metal binding modes -- Current working model of Abeta toxicity -- Abeta amyloid protein: current model consistent with EXAFS -- Metal-protein attenuating compound (MPAC) with moderate affinity for metals -- Clioquinol (CQ, PBT1) the prototypic MPAC -- PBT2: SAR based on rational drug design -- CQ (PBT1) vs. …”
Get full text
Series (Alzheimer disease)
Series (Drug discovery and development in the neurosciences)

Alzheimer's disease where are we up to? /

Table of Contents: “…Contents: Advances in technology -- Alzheimer: senile plaques -- Examples of risk loci for Alzheimer's disease (AD) -- TREM2 mutations in AD -- Genomic analysis of Alzheimer's disease -- Plaque and amyloid pathology -- Lipid metabolism in the aetiology of AD -- Risk factors expressed in the innate immune system -- Implications for therapy.…”
Get full text
Series (Periodic reports)
Series (Alzheimer's disease)

Alzheimer's disease where are we up to? /

Table of Contents: “…Contents: Advances in technology -- Alzheimer: senile plaques -- Examples of risk loci for Alzheimer's disease (AD) -- TREM2 mutations in AD -- Genomic analysis of Alzheimer's disease -- Plaque and amyloid pathology -- Lipid metabolism in the aetiology of AD -- Risk factors expressed in the innate immune system -- Implications for therapy.…”
Get full text
Series (Periodic reports)
Series (Alzheimer's disease)

Alzheimer's disease where are we up to? /

Table of Contents: “…Contents: Advances in technology -- Alzheimer: senile plaques -- Examples of risk loci for Alzheimer's disease (AD) -- TREM2 mutations in AD -- Genomic analysis of Alzheimer's disease -- Plaque and amyloid pathology -- Lipid metabolism in the aetiology of AD -- Risk factors expressed in the innate immune system -- Implications for therapy.…”
Get full text
Series (Periodic reports)
Series (Alzheimer's disease)